论文部分内容阅读
目的探讨EphB2受体在胃癌组织、癌前病变中的表达及对血管生成和肿瘤生物学行为的影响。方法应用链霉素亲生物素-过氧化酶免疫组织化学法(S-P)检测75例胃癌组织、45例癌前病变中EphB2的表达情况并与30例正常胃黏膜组织对照,采用CD34标记血管内皮细胞,计算微血管密度(MVD)。结果EphB2在胃癌组织及癌前病变表达高于正常胃黏膜组织,分别为64.0%、33.3%和10.0%,三者差异存在显著性(H=29.113,P<0.001)。EphB2在胃癌组织不同临床病理分期表达不同,分别为0、33.3%、52.2%、80.0%和100.0%,随临床病理分期增加表达率呈上升趋势(H=23.518,P<0.001)。CD34(以MVD表示)在胃癌组织、癌前病变及正常胃黏膜表达分别为67.61±13.13、33.92±3.60和21.29±3.28,呈下降趋势(F=318.831,P<0.001)。EphB2与CD34(以MVD表示)在胃癌组织中皆呈高表达,两者呈正相关(rs=0.915,P<0.001)。结论EphB2在胃癌组织中表达并随临床病理分期增加表达率呈上升趋势,EphB2在部分癌前病变中表达,EphB2参与肿瘤血管形成。
Objective To investigate the expression of EphB2 receptor in gastric carcinoma and precancerous lesions and its effect on angiogenesis and tumor biological behavior. Methods The expression of EphB2 in 75 cases of gastric cancer and 45 cases of precancerous lesions was detected by streptavidin-peroxidase immunohistochemistry (SP). The expression of EphB2 in 30 cases of normal gastric mucosa was detected by CD34-labeled vascular endothelium Cells were counted for microvessel density (MVD). Results The expression of EphB2 in gastric cancer tissues and precancerous lesions was significantly higher than that in normal gastric mucosa (64.0%, 33.3% and 10.0%, respectively). There was significant difference between the two groups (H = 29.113, P <0.001). The expression of EphB2 was different in different clinicopathological stages of gastric cancer (0, 33.3%, 52.2%, 80.0% and 100.0%, respectively). The expression of EphB2 was up-regulated with the clinicopathological stage (H = 23.518, P <0.001). The expression of CD34 in MVD was 67.61 ± 13.13,33.92 ± 3.60 and 21.29 ± 3.28 in gastric cancer tissue, precancerous lesions and normal gastric mucosa, respectively, showing a decreasing trend (F = 318.831, P <0.001). Both EphB2 and CD34 (expressed as MVD) were highly expressed in gastric cancer tissues, and there was a positive correlation between them (rs = 0.915, P <0.001). Conclusion The expression of EphB2 in gastric cancer tissues increases with the increase of clinical pathological stage, EphB2 is expressed in some precancerous lesions, and EphB2 is involved in tumor angiogenesis.